As a leading manufacturer of micro-chemiluminescence analyzers in China, the “Aurora” M2 microfluidic chemiluminescence analyzer developed by Wahmeixing Microtechnologies incorporates three core technologies: microfluidics+magnetic particle separation+POCT. It is the world's first microfluidic chemiluminescence analysis system, with the features of precision, miniaturization, and stupidity. It weighs only 5KG, and its detection accuracy is comparable to that of a large-scale chemiluminescence inspection device. It is praised by experts as its leader POCT4. .0 Times'!
The completion of the new round of financing is not only a recognition of the market status of Huamai Xingwei’s existing products, but also a new impetus for the rapid development of Huamai Xingwei. 'For Huamai Xing, which is about to start large-scale production and sales, The completion of the A+ round of financing will be even stronger. Mr. Li Quan, Chairman of China Maixin Micro, stated that 'this round of financing funds is mainly used for the production and sales of miniature chemiluminescence analyzer (M2), M5, M7, MD01 instrument series and more. R&D and application of clinical reagents, Huamai Xingwei will further increase product development and registration reporting, enrich the types of reagent certification, open up new markets and opportunities, and contribute to China's POCT undertaking.
Good words to attract outstanding, excellent excellence in excellence. Huamai Xingwei's technology leadership in the product and the brand's market recognition, to attract various financing parties, the round of financing is not small.
Shenzhen Yingtai Shunkang Venture Capital Partnership (Limited Partnership) is a national medical industry guidance fund. The funders include the National Development and Reform Commission, Shenzhen Guiding Fund Investment Co., Ltd., Zhongyuan Xihe Cell Gene Engineering Co., Ltd., China Yinhong, etc. , The management fund has a scale of about 5 billion yuan. It has a professional investment team in the field of biomedicine, pensions, and real estate. It has rich experience in investment management and operation. Both parties will supply high-quality antibody raw materials in the future, accompanied by heart failure/cardiocerebral vascular drugs. , Elderly health examination, chronic disease management, immune cell storage along with detection and other directions have a broad space for cooperation.
Shanghai Bowei Yicheng Investment (Group) Co., Ltd., Shandong Jiangyan Venture Capital Co., Ltd. is also famous in the industry. In fact, the total amount of capital and investment reached 800 million yuan and 400 million yuan respectively.
'I believe that the entry of capital will further contribute to the rapid development of Huamai Micro's development, injecting new momentum into the production and sales of existing products, and the development and application of new products,' Chairman Li Quan said. In addition to capital investment, various investors in the medical, pharmaceutical, physical examination, pension, chronic disease management and many other industrial resources will also work together to promote the localization of POCT equipment.